Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$113.20 USD
-2.90 (-2.50%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $109.00 -4.20 (-3.71%) 5:24 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JAZZ 113.20 -2.90(-2.50%)
Will JAZZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
Other News for JAZZ
Jazz Pharmaceuticals (JAZZ) Adjusts FY25 Revenue Outlook
Earnings Scheduled For August 5, 2025
Jazz Pharmaceuticals Q2 2025 Earnings: Revenue Hits $1.05 Billion, EPS Falls Short at -$11.74
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial ...
Jazz narrows FY25 EPS view $4.80-$5.60 from $4.00-$5.60